BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 18674698)

  • 1. Positron emission tomography for the diagnosis and management of patients with gastrointestinal malignancies.
    Saga T; Nakamoto Y; Higashi T; Yoshikawa K
    Gastrointest Endosc Clin N Am; 2008 Jul; 18(3):479-93, ix. PubMed ID: 18674698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of positron emission tomography-computed tomography in gastrointestinal malignancies.
    Banks KP; Song WS
    Radiol Clin North Am; 2013 Sep; 51(5):799-831. PubMed ID: 24010907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [18F]Fluorodeoxyglucose PET/Computed Tomography in Gastrointestinal Malignancies.
    Donswijk ML; Hess S; Mulders T; Lam MG
    PET Clin; 2014 Oct; 9(4):421-41, v-vi. PubMed ID: 26050945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors.
    Gayed I; Vu T; Iyer R; Johnson M; Macapinlac H; Swanston N; Podoloff D
    J Nucl Med; 2004 Jan; 45(1):17-21. PubMed ID: 14734662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 18F-FDG PET for evaluation of the treatment response in patients with gastrointestinal tract lymphomas.
    Kumar R; Xiu Y; Potenta S; Mavi A; Zhuang H; Yu JQ; Dhurairaj T; Dadparvar S; Alavi A
    J Nucl Med; 2004 Nov; 45(11):1796-803. PubMed ID: 15534046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [[18F]-FDG-PET in the diagnostics of gastrointestinal tumors].
    Buchmann I; Ganten TM; Haberkorn U
    Z Gastroenterol; 2008 Apr; 46(4):367-75. PubMed ID: 18393156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gastrointestinal tract malignancies and positron emission tomography: an overview.
    Esteves FP; Schuster DM; Halkar RK
    Semin Nucl Med; 2006 Apr; 36(2):169-81. PubMed ID: 16517238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Roles of F-18 FDG PET or PET/CT for the evaluation of gastrointestinal malignancies].
    Yun M; Kim BI
    Korean J Gastroenterol; 2006 Dec; 48(6):378-87. PubMed ID: 17189920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
    Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
    Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Diagnosis of gastrointestinal tract malignancies using positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG)].
    Kato H; Sohda M; Kuwano H
    Nihon Shokakibyo Gakkai Zasshi; 2004 Dec; 101(12):1292-301. PubMed ID: 15651391
    [No Abstract]   [Full Text] [Related]  

  • 11. Gastrointestinal malignancies evaluated with (18)F-fluoro-2-deoxyglucose positron emission tomography.
    Chin BB; Chang PP
    Best Pract Res Clin Gastroenterol; 2006 Feb; 20(1):3-21. PubMed ID: 16473798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PET/CT in oncology: integration into clinical management of lymphoma, melanoma, and gastrointestinal malignancies.
    Schöder H; Larson SM; Yeung HW
    J Nucl Med; 2004 Jan; 45 Suppl 1():72S-81S. PubMed ID: 14736838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular positron emission tomography and PET/CT imaging in urological malignancies.
    Powles T; Murray I; Brock C; Oliver T; Avril N
    Eur Urol; 2007 Jun; 51(6):1511-20; discussion 1520-1. PubMed ID: 17275167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18F-FDG-PET/CT Imaging for Gastrointestinal Malignancies.
    Howard BA; Wong TZ
    Radiol Clin North Am; 2021 Sep; 59(5):737-753. PubMed ID: 34392916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of FDG-PET in the diagnosis and treatment of colorectal liver metastases.
    Wiering B; Ruers TJ; Oyen WJ
    Expert Rev Anticancer Ther; 2004 Aug; 4(4):607-13. PubMed ID: 15270664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Positron emission tomography in colorectal cancer.
    Flamen P
    Best Pract Res Clin Gastroenterol; 2002 Apr; 16(2):237-51. PubMed ID: 11969236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Positron emission tomography in gynecological malignancies.
    Kumar R; Chauhan A; Jana S; Dadparvar S
    Expert Rev Anticancer Ther; 2006 Jul; 6(7):1033-44. PubMed ID: 16831075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of 18F-fluoro-deoxy-glucose positron emission tomography (FDG-PET) in the management of patients with colorectal cancer.
    Pelosi E; Deandreis D
    Eur J Surg Oncol; 2007 Feb; 33(1):1-6. PubMed ID: 17126522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
    Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
    BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.